Abstract

BackgroundVenom immunotherapy (VIT) is an effective treatment for subjects with systemic allergic reactions (SR) to Hymenoptera stings, however there are few studies concerning the relevance of the venom specific IgE changes to decide about VIT cessation. We assessed IgE changes during a 5-year VIT, in patients stung and protected within the first 3 years (SP 0–3) or in the last 2 years (SP 3–5), and in patients not stung (NoS), to evaluate possible correlations between IgE changes and clinical protection.MethodsYellow jacket venom (YJV)-allergic patients who completed 5 years of VIT were retrospectively evaluated. Baseline IgE levels and after the 3rd and the 5th year of VIT were determined; all patients were asked about field stings and SRs.ResultsA total of 232 YJV-allergic patients were included and divided into the following groups: 84 NoS, 72 SP 0–3 and 76 SP 3–5. IgE levels decreased during VIT compared to baseline values (χ2 = 346.029, p < 0.001). Recent vespid stings accounted for significantly higher IgE levels despite clinical protection. IgE levels after 5 years of VIT correlated significantly with Mueller grade (F = 2.778, p = 0.012) and age (F = 6.672, p = 0.002). During follow-up from 1 to 10 years after VIT discontinuation, 35.2 % of the contacted patients reported at least one field sting without SR.ConclusionsThe yellow jacket-VIT temporal stopping criterion of 5 years duration did not result in undetectable IgE levels, despite a long-lasting protection. A mean IgE decrease from 58 to 70 % was observed, and it was less marked in elderly patients or in subjects with higher Mueller grade SR.

Highlights

  • Venom immunotherapy (VIT) is an effective treatment for subjects with systemic allergic reactions (SR) to Hymenoptera stings, there are few studies concerning the relevance of the venom specific IgE changes to decide about VIT cessation

  • Pravettoni et al Clin Mol Allergy (2015) 13:29 are scarce, especially regarding patients not stung during VIT, in whom the actual clinical protection is unknown

  • We retrospectively evaluated the decrease in specific IgE (sIgE) over 5 years of VIT in 3 groups of yellow jacket venom (YJV)-allergic patients: subjects stung and protected within the first 3 years or within the last 2 years of VIT, and patients not stung during the VIT course

Read more

Summary

Introduction

Venom immunotherapy (VIT) is an effective treatment for subjects with systemic allergic reactions (SR) to Hymenoptera stings, there are few studies concerning the relevance of the venom specific IgE changes to decide about VIT cessation. Venom immunotherapy (VIT) is an effective treatment for patients suffering from hymenoptera venom allergy (HVA) with severe systemic reaction (SR) and documented sensitization to the causative venom [1]. The optimal duration of VIT necessary to achieve longterm protection has been evaluated in several studies, aimed to identify useful parameters for a safe stopping [2,3,4]. The physician may be reluctant to stop VIT even when the temporal criterion is reached, because studies evaluating the relevance of the observed declines in sIgE to decide about VIT cessation

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call